Cocrystal Pharma, Inc. (18)
Browse by Contract Category
Contracts
-
Consulting and Scientific Advisory Board Agreement, dated April 13, 2021 with Roger Kornberg
(Filed With SEC on August 16, 2021)
-
Underwriting Agreement, dated as of May 4, 2021 by and between Cocrystal Pharma, Inc. and H.C. Wainwright & Co., LLC
(Filed With SEC on May 5, 2021)
-
License Agreement dated April 19, 2020, between the Company and Kansas State University Research Foundation
(Filed With SEC on August 6, 2020)
-
At-The-Market Offering Agreement, dated July 1, 2020, by and between Cocrystal Pharma, Inc. and H.C. Wainwright & Co., LLC
(Filed With SEC on July 2, 2020)
-
Placement Agency Agreement, dated as of January 29, 2020, by and between Cocrystal Pharma, Inc. and A.G.P./Alliance Global Partners
(Filed With SEC on January 31, 2020)
-
Amended and Restated Underwriting Agreement, dated as of August 26, 2020, by and between Cocrystal Pharma, Inc. and H.C. Wainwright & Co., LLC
(Filed With SEC on August 27, 2020)
-
License Agreement, dated February 18, 2020, between the Company and Kansas State University Research Foundation
(Filed With SEC on May 13, 2020)
-
Description of Capital Stock
(Filed With SEC on March 27, 2020)
-
Form of Securities Purchase Agreement, dated March 9, 2020, by and between the Company and the Purchasers
(Filed With SEC on March 13, 2020)
-
Engagement letter dated February 26, 2020 by and between the Company and H.C. Wainwright & Co., LLC
(Filed With SEC on March 4, 2020)
-
Form of Securities Purchase Agreement, dated February 27, 2020, by and between the Company and the Purchasers
(Filed With SEC on March 4, 2020)
-
Form of Securities Purchase Agreement
(Filed With SEC on January 31, 2020)
-
Amendment to the Amended and Restated Equity Distribution Agreement, dated October 2, 2019
(Filed With SEC on January 29, 2020)
-
Underwriting Agreement, dated as of October 30, 2019, by and between Cocrystal Pharma, Inc. and Aegis Capital Corp
(Filed With SEC on October 31, 2019)
-
Amended and Restated Equity Distribution Agreement, dated October 30, 2019
(Filed With SEC on October 30, 2019)
-
Exclusive License and Research Collaboration Agreement between the Company and Merck Sharp & Dohme Corp., dated January 2, 2019
(Filed With SEC on April 1, 2019)
-
Amendment to Equity Distribution Agreement, dated March 20, 2019
(Filed With SEC on March 26, 2019)
-
Securities Purchase Agreement, dated March 11, 2019
(Filed With SEC on March 11, 2019)